By Peter Geschek:Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.A new wave of immunotherapy drugs, in the spotlight of the upcoming ASCO (American Society of Clinical Oncology) meeting, promises to produce longer-lasting remissions.
By Peter Geschek:In February Merck (MRK) has signed three collaboration agreements with Amgen (AMGN), Incyte (INCY) and Pfizer (PFE), to conduct separate clinical trials combining Merck's anti-PD-1 therapy MK-3475
By Investment Directions: We had great news today (Thursday), but the response was tepid. Rather than being disappointed or dismissing the news, here is why we should be excited at both the developments and the investment potential it opens up.
Roche Holding AG (RHHBY) announced today that the investigational drug, cobimetinib, proved effective in treating melanoma skin cancer when used with another of the company’s drugs, Zelboraf. Phase III results, with 495 patients in the study, revealed that using the drug medley helped people with advanced melanoma live longer without the disease worsening. Detailed data will be presented at an upcoming medical meeting.
The side effects John-Peter Bradford endured four years ago as he underwent radiation therapy and surgery for throat cancer were, he says, “barbaric.” Still, the potent treatment worked, eradicating the tumour and saving his life.
As his family confronts the shock of another, more advanced malignancy today, however, the Ottawa management consultant is agonizingly aware that many cancers remain incurable, despite 40 years of hugely expensive research into the disease and how to treat it.
Prohost Biotech submits:One year ago, an anaplastic lymphoma kinase (ALK) inhibitor called crizotinib developed by Pfizer (PFE) for non-small-cell lung cancer demonstrated it shrank the tumors in most of the 82 patients after two months of treatment.
The US Food and Drug Administration said Monday it had approved a drug currently used in patients with advanced kidney cancer to treat brain tumors caused by a rare genetic disease.Everolimus, which is marketed under the name Afinitor by Novartis, was approved to treat tumors caused by the genetic condition tuberous sclerosis that cannot be treated with surgery, the FDA said in a statement.Tuberous sclerosis causes slow-growing non-cancerous tumors called subependymal giant cell astrocytoma (SEGA) in the brain and other parts of the body.